Systematic review, meta-analysis and economic modelling of ...

More documents

Recommendations

Info

Assessment of diagnostic and prognostic accuracyTABLE 22 Univariate analyses reported in prognostic biomarker studies (continued)Study Biomarker ThresholdBiomarkerselection Analysis FindingBrugger-Anderson CRP Quartiles None Log-rank test p
DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 1TABLE 22 Univariate analyses reported in prognostic biomarker studies (continued)Study Biomarker ThresholdBiomarkerselection Analysis FindingMcCann 2009 111 MPO 421 ng/ml None Univariate OR 0.8 (95% CI 0.4 to 1.6)Cameron 2007 94 Myoglobin 61 ng/ml None Univariate RR 3.1 (95% CI 1.7 to 5.7)De Winter 1996 96 Myoglobin 90 ng/ml None Univariate RR 1.0 (95% CI 0.3 to 3.2)Fromm 2001 98 Myoglobin 85 ng/ml None Univariate RR 1.6 (95% CI 1.1 to 2.9)Green 200099 Myoglobin 69 ng/ml None Univariate RR 3.4 (95% CI 2.2 to 5.1)Hills 2003 100 Myoglobin 100 ng/ml None Univariate RR 2.2 (95% CI 1.3 to 4.0)Jaffery 2008 101 Myoglobin 200 ng/ml None NR –Kontos 2007 104 Myoglobin 90 ng/ml None Univariate RR 3.7 (95% CI 2.8 to 4.7)Lim 2002 106 Myoglobin 116 ng/ml All Univariate OR 12.5 (95% CI 2.1 to 71)Mathew 1999 110 Myoglobin 92 µg/l None Univariate RR 2.5McCord 2003 112 Myoglobin 200 ng/ml None Sensitivity andspecificity74.8 (95% CI 65 to 83) and70.4 (95% CI 67 to 74)Newby 2001 114 Myoglobin 105 ng/ml None NR –Ordonez-Llanos Myoglobin Quartiles None Univariate OR 5.2 (95% CI 3.0- 9.2)2006 115Sonel 2000 117 Myoglobin 100 µg/ml None Univariate OR 2.5 (95% CI 1.3 to 4.6)Svensson 2004 118 Myoglobin 50 ng/ml None Fishers exact test p = 0.07Symanski 2007 119 Myoglobin 82 ng/ml None AUROC 0.78 (95% CI 0.72 to 0.83)Van Domberg Myoglobin 64 µg/ml (women),2000 120 76 µg/ml (men)NoneNRCameron 2007 94 NT-pro-BNP 280 ng/ml None Univariate RR 3.0 (95% CI 1.6 to 5.7)Mockel 2008 86 NT-pro-BNP 145 ng/ml None Univariate OR 3.8 (95% CI 1.9 to 7.5)Apple 2007 87 NT-pro-BNP < 75 years,125 ng/l ≥ 75 years,450 ng/lNone Univariate RR 2.9 (95% CI 1.1 to 7.4)Eggers 2008 85 NT-pro-BNP 550 ng/l None Chi-squared test p < 0.001Eggers 2008 97 NT-pro-BNP Not stated None Univariate OR 1.8 (95% CI 1.4 to 2.3)Jernberg 2002 102 NT-pro-BNP Quartiles None Log-rank test Q1: ReferenceQ2: p = 0.005Q3: p < 0.001Q4: p < 0.001McCann 2009 111 NT-pro-BNP 1371 ng/l None Univariate OR 5.4 (95% CI 3.0 to 9.7)Yamashita 2010 122 NT-pro-BNP None: continuous None Univariate OR 1.0 (95% CI 1.0 to 1.0)Body 2011 46 PAPP-A Tertiles Tn –ve Mantel–Haenszel testp = 0.619Kavsak 2009 103 PAPP-A Tertiles None Log-rank test p = 0.05Laterza 2004 105 PAPP-A 0.22 mIU/l None Univariate RR 4.7 (95% CI 2.2 to 9.8)Lund 2003 107 PAPP-A 2.9 mIU/l Tn –ve Univariate RR 2.3 (95% CI 1.1 to 5.0)McCann 2009 111 PAPP-A 12.4 ng/ml None Univariate OR 1.1 (95% CI 0.6 to 2.2)continued© Queen’s Printer and Controller of HMSO 2013. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of Statefor Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journalsprovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton SciencePark, Southampton SO16 7NS, UK.63
Page 1:
Health Technology AssessmentVOLUME
Page 7:
DOI: 10.3310/hta17010 Health Techno
Page 10 and 11:
ContentsAppendix 5 Expected discoun
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19:
Page 22 and 23:
BackgroundTABLE 1 Hospital admissio
Page 24 and 25:
Background2. investigation of the c
Page 26 and 27:
BackgroundComputed tomographic coro
Page 28 and 29:
Research questionsiii. the diagnost
Page 30 and 31:
Assessment of diagnostic and progno
Page 32 and 33: Assessment of diagnostic and progno
Page 91 and 92: DOI: 10.3310/hta17010 Health Techno
Page 125: DOI: 10.3310/hta17010 Health Techno
Page 128 and 129: Discussionspecificity were 62% (95%
Page 130 and 131: Discussionneed for revascularisatio
Page 132 and 133:
Discussionchanges in sensitivity an
Page 134 and 135:
Discussionuncertainty about these p
Page 136 and 137:
Discussiontroponin assays have bett
Page 138 and 139:
ConclusionsSuggested research prior
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151:
Page 154 and 155:
Appendix 144. heart-type fatty acid
Page 156 and 157:
Appendix 1135. interleukin 33.mp. (
Page 158 and 159:
Appendix 147. 37 and 45 (529)48. li
Page 161:
Page 164 and 165:
Appendix 313. Fernandez Portales JG
Page 166 and 167:
Appendix 346. Luscher MS, Ravkilde
Page 168 and 169:
Appendix 316. Rao SV, Ohman EM, Gra
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195:
Page 198 and 199:
Appendix 9Clinical diagnosis of NST
Page 200 and 201:
Appendix 9respectively. Exercise EC
Page 202 and 203:
Appendix 93. Two reviewers will mak
Page 204 and 205:
Appendix 9The methodology used in t
Page 206 and 207:
Appendix 9ES (Information Resources
Page 208:
Appendix 923. Westwood ME, Whiting
show all

Systematic review, meta-analysis and economic modelling of ...

Create successful ePaper yourself

Delete template?

Save as template?